Clinical Trial: Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726069) titled 'Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department' on July 21.

Brief Summary: Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Cannabinoid Hyperemesis Syndrome

Intervention: DRUG:...